依维莫司联合内分泌药物治疗内分泌耐药型激素受体阳性晚期乳腺癌回顾性分析  

Retrospective Analysis of Everolimus Combined with Endocrine Drugs in Treatment of Endocrine-resistant Hormone Receptor-positive Advanced Breast Cancer

作　　者：邓素华[1] 闻国权[1] 董菊红[1] DENG Suhua;WEN Guoquan;DONG Juhong

机构地区：[1]广东省惠州市第三人民医院

出　　处：《中国医学创新》2019年第18期26-29,共4页Medical Innovation of China

摘　　要：目的:分析依维莫司联合内分泌药物治疗内分泌耐药型激素受体阳性晚期乳腺癌的效果和不良反应。方法:选取2017年2月-2019年2月31例本院乳腺科接受依维莫司联合内分泌药物治疗内分泌耐药型激素受体阳性晚期乳腺癌作为研究对象,回顾性分析其治疗情况、临床疗效、影响因素及不良反应。结果:31例患者治疗时间为1~22个月,其中2例患者仅治疗1个月;费用难以承担、不能耐受停药各2例;PR 5例(18.52%),SD 18例(66.67%),PD 4例(14.81%);mPFS 1~21个月,中位mPFS为7.0个月;ORR为18.52%,CBR为40.74%;内脏无转移、一线治疗的患者mPFS显著延长,差异均有统计学意义(P<0.05);激素受体状态阳性高、转移部位数目少、既往姑息治疗有延长mPFS的趋势,但差异均无统计学意义(P>0.05);不良反应以口腔溃疡最为常见,发生率为96.30%。结论:依维莫司联合内分泌药物治疗内分泌耐药型激素受体阳性晚期乳腺癌具有一定的效果,能延长患者的生存时间,延缓病情进展,但是对患者可耐受剂量、疗效影响因素及如何控制不良反应尚需进一步研究。Objective:To analyze the efficacy and side effects of Everolimus combined with endocrine drugs in the treatment of endocrine-resistant hormone receptor-positive advanced breast cancer.Method:A total of 31 cases of oncology treated with Everolimus combined with endocrine drugs for endocrine-resistant hormone receptor-positive advanced breast cancer from February 2017 to February 2019 were selected as the objects.The treatment,clinical efficacy,influencing factors and adverse reactions of patients were retrospectively analyzed.Result:The treatment time of 31 patients was 1 to 22 months.Among them,2 patients were only treated for1 month.There were 2 cases of withdrawal(the cost was difficult to bear),and 2 cases were stopped(they could not tolerate).5 cases of PR,accounted for 18.52%,18 cases of SD,accounting for 66.67%,4 cases of PD,accounting for 14.81%.mPFS:1 to 21 months,the median mPFS was 7.0 months.ORR was 18.52%,and CBR was40.74%.The mPFS of patients with visceral non-metastasis and first-line treatment were significantly prolonged,the differences were statistically significant(P<0.05).The hormone receptor status was positive,and the metastasis was high,the number of sites was small,and the previous palliative treatment had a tendency to prolong mPFS,but the differences were not statistically significant(P>0.05).The most common adverse reaction was oral ulcer,the incidence rate was 96.30%.Conclusion:Everolimus combined with endocrine drugs in the treatment of endocrine-resistant hormone receptor-positive advanced breast cancer has a certain effect,prolonging the survival time of patients and delaying the progression of the disease,but further research is needed on the patient tolerable dose,the influencing factors of efficacy and how to control adverse reactions.

关 键 词：依维莫司 内分泌耐药 激素受体 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]